Imricor Medical Systems, Inc. · ASX:IMR
Imricor Medical Systems — Shareholder Meeting (May 2021)
15 slides from Imricor Medical Systems's shareholder meeting presentation, May 6, 2021
Slide 1: Welcome to the Imricor Annual Meeting
For personal use only Welcome to the Thursday, 6 May 2021 (AEST) Imricor Annual Meeting Wednesday, 5 May 2021 (CDT)
Slide 2: Please submit questions at any time throughout the meeting
Please submit questions at any time throughout the meeting For personal use only When the Question function is available, the Q&A icon will appear at the top of the app To send in a question, click in the ‘Ask a question’ box, type your question and press the send arrow Your question will be sent im
Slide 3: Voting online at the virtual meeting
Voting online at the virtual meeting For personal use only When the poll is open, the vote will be accessible by selecting the voting icon at the top of the screen To vote simply select the direction in which you would like to cast your vote. The selected option will change colour For Against Abstai
Slide 4: Imricor's Board of Directors
Imricor’s Board of Directors For personal use only Steve Wedan Mark Tibbles Anita Messal Peter McGregor President and CEO, Deputy Chair and Lead Non-executive Director Non-executive Director and Chair Independent Director 4 Imricor Annual Meeting 2021
Slide 5: Chair's Address
Chair’s Address For personal use only 5 Imricor Annual Meeting 2021
Slide 6: Managing through COVID-19
Managing through COVID-19 For personal use only • Due to hospital closures associated with strict COVID-19 containment measures implemented across key target geographies of Germany and the Netherlands, Imricor experienced delays in signing agreements with new clinical sites in the last quarter of 20
Slide 7: COVID-19 situation in key target geographies
COVID-19 situation in key target geographies Daily cases (7 day average) to 30 Apr 2021 For personal use only 30,000 • Signed five new agreements in a six-week period during Recommencement of cases in MUMC+ September and October 25,000 and Leipzig Signed 5 new • Hard lock downs in mid-December resul
Slide 8: Vaccination situation in key target geographies
Vaccination situation in key target geographies % Share of people who received at least one dose of For personal use only COVID-19 vaccine 25 • A new wave of COVID-19 combined with disappointing vaccination rollout in late March / early 20 April resulted in the reinstatement of stricter containment
Slide 9: Partnering to drive growth in clinical sites
Partnering to drive growth in clinical sites Imricor entered into a number of agreements in 2020 that promote future iCMR site adoption For personal use only • A worldwide leading • Largest Group Purchasing • Leading provider of • Leading German producer • Australian-owned medical manufacturer of MR
Slide 10: Developing product lines to support expanded indications & margin improvement
Developing product lines to support expanded indications & margin improvement Steerable Sheath and Diagnostic Catheter For personal use only Transseptal Needle • Development complete and • Development phase submitted for CE mark • Fully staffed execution certification • On track to be ready for • Sc
Slide 11: Lab rollout plans underpinned by strong pipeline
Lab rollout plans underpinned by strong pipeline Nine clinical sites now contracted across Germany, The Netherlands & France • Dresden Heart Centre, Germany, a training Centre of Excellence For personal use only • Haga Hospital, The Netherlands 10 sites with • Amsterdam University Medical Centre, Th
Slide 12: A phased approach to Geographic Expansion
A phased approach to Geographic Expansion Europe For personal use only CE mark received We have established sales force targeting Germany and the Netherlands Remain on track to targeting a clinical trial for VT Ablations in late 2021 – early 2022 Helios Hospital Berlin-Buch United States FDA strateg
Slide 13: Continued investment in business capability and capacity to deliver growth
Continued investment in business capability and capacity to deliver growth Workforce growth continues to expand capability across the company with 27 new hires in 2020 to support commercialisation and growth strategies, including hires from high calibre organisations within For personal use only the
Slide 14: Our focus for the year ahead
Our focus for the year ahead Imricor’s focus for 2021 is on accelerating its product launch throughout the EU while pursuing For personal use only growth opportunities that position the company strongly in the coming years Commercialisation • Continued site adoption with focus on acceleration in the
Slide 15: Disclaimer
Disclaimer The material contained in this presentation is intended to be general background information on Imricor Medical Systems Inc (“Imricor”) and its activities. For personal use only The information is supplied in summary form and is therefore not necessarily complete. It is not intended that
Imricor Medical Systems — Shareholder Meeting (May 2021) on 6ix